Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254760 | 0.92 | DRD2 (0.64) | DRD2SIGMAR1TDP1GAAMEN1 | |
| SCHEMBL13609474 | 0.88 | DRD2 (0.60) | DRD2SIGMAR1TDP1GAAMEN1 | |
| SCHEMBL9127008 | 0.88 | DRD2 (0.60) | DRD2SIGMAR1TDP1GAAMEN1 | |
| SCHEMBL30380945 | 0.87 | DRD2 (0.59) | DRD2SIGMAR1TDP1GAAMEN1 | |
| SCHEMBL30380052 | 0.87 | TDP1 (0.64) | DRD2SIGMAR1TDP1GAAMEN1 | |
| SCHEMBL16708685 | 0.87 | DRD2 (0.59) | DRD2SIGMAR1TDP1GAAMEN1 | |
| SCHEMBL3524057 | 0.86 | DRD2 (0.66) | DRD2SIGMAR1TDP1MAOAMAOB | |
| SCHEMBL5031371 | 0.86 | DRD2 (0.48) | DRD2SIGMAR1TDP1MAOAMAOB | |
| SCHEMBL23786468 | 0.85 | DRD2 (0.58) | DRD2SIGMAR1TDP1GAAMEN1 | |
| SCHEMBL30048478 | 0.85 | DRD2 (0.45) | DRD2SIGMAR1TDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20200407325-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-12-31 | — | — | US | disclosed |
| US-20200407325-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-12-31 | — | — | US | disclosed |
| US-10807958-B2 | 1,4-bis(3-aminopropyl)piperazine derivative and its use | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-20 | — | — | US | disclosed |
| US-10807958-B2 | 1,4-bis(3-aminopropyl)piperazine derivative and its use | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-20 | — | — | US | disclosed |
| EP-3271335-B1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | INST NAT SANTE RECH MED (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-20180290981-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-10-11 | — | — | US | disclosed |
| US-10017476-B2 | 1,4-bis(3-aminopropyl)piperazine derivative and its use | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-07-10 | — | — | US | disclosed |
| US-10017476-B2 | 1,4-bis(3-aminopropyl)piperazine derivative and its use | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-07-10 | — | — | US | disclosed |
| EP-3013824-B1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-20180072679-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | INSERM ( INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-03-15 | — | — | US | disclosed |
| US-20180072679-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | INSERM ( INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-03-15 | — | — | US | disclosed |
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
| WO-2012104788-A2 | ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-09 | — | — | WO | disclosed |
| US-8048536-B2 | Single-layer organic EL device | MITSUBISHI HEAVY INDUSTRIES LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-1856059-B1 | MULTIMERS OF PYRIMIDINONE DERIVATIVES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20070116981-A1 | Single-layer organic el device | ISOBE, SHINICHIRO (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-0144744-A2 | Specific binding assay based on enzyme cascade amplification | MILES LABORATORIES, INC. (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0087564-A1 | Specific binding assay method, reagent system and labelled conjugate for use in this method | MILES LABORATORIES, INC. (US) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072679-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | MAPT, PSEN1, PSEN2 | DRD2 2189/4885SIGMAR1 558/4885TDP1 174/4885 |
| US-10807958-B2 | 1,4-bis(3-aminopropyl)piperazine derivative and its use | MAPT, PSEN1, PSEN2 | DRD2 2076/4885SIGMAR1 1052/4885TDP1 135/4885 |
| US-20180290981-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | MAPT, PSEN1, PSEN2 | DRD2 2189/4885SIGMAR1 558/4885TDP1 174/4885 |
| US-10017476-B2 | 1,4-bis(3-aminopropyl)piperazine derivative and its use | MAPT, PSEN1, PSEN2 | DRD2 2076/4885SIGMAR1 1052/4885TDP1 135/4885 |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | DRD2 454/4885SIGMAR1 923/4885TDP1 285/4885 |
| US-20200407325-A1 | NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE | MAPT, PSEN1, PSEN2 | DRD2 2189/4885SIGMAR1 558/4885TDP1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.